MabThera® / Rituxan®
Rituximab is a chimeric monoclonal antibody targeting CD20 on B cells. Used in non-Hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune conditions.
| Dosage Form | IV Injectable (Solution) |
| Strength | 10 mg/mL; 100 mg, 500 mg vials |
| Storage | Store at 2–8°C. Protect from direct sunlight. |
| Category | Oncology |
| Availability | Available for Transfer |
Non-Hodgkin lymphoma (follicular, DLBCL); chronic lymphocytic leukemia; rheumatoid arthritis; granulomatosis with polyangiitis.
Binds to CD20 antigen on pre-B and mature B lymphocytes, mediating B-cell lysis through complement-dependent cytotoxicity (CDC) and ADCC.
Each Burrard Pharmaceuticals technology transfer package for Rituximab includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.